Enanta Pharmaceuticals Inc., of Watertown, Mass., reported results from the PEARL-II, PEARL-III, PEARL-IV and TURQUOISE-II studies, which are the remaining Phase III studies of the six Phase III registrational studies being conducted by Chicago-based Abbvie Inc. for the treatment of genotype 1 (GT1) hepatitis C virus (HCV) infection using a regimen containing Enanta’s lead protease inhibitor ABT-450.